Phase 1 · NCT05445232
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes
CompletedVerified
Registry record
Trial details
- Trial
- A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- ClinicalTrials.gov ID
- NCT05445232
- Indication
- Obesity
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 32
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Midazolam; Drug: Warfarin; Drug: Caffeine
- Comparator
- Not reported
- Eligible ages
- 18 Years – 70 Years
- Locations
- 2 sites · United States
- Study start
- 8 Jul 2022
- Primary completion
- 24 Feb 2023
- Study completion
- 24 Feb 2023
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 18 Apr 2023
Endpoints
Primary
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam; PK: Maximum Observed Concentration (Cmax) of Midazolam; PK: AUC[0-∞] of Warfarin; PK: Cmax of Warfarin; PK: AUC[0-∞] of Caffeine; PK: Cmax of Caffeine